Greehey CCRI Seminar Series – Diana Hargreaves, PhD (Salk Institute)
Share This Event
Share This Event
The Hargreaves lab is interested in epigenetic regulation mediated by BAF chromatin remodeling complexes. Chromatin remodeling complexes create DNA accessibility by hydrolyzing ATP, allowing the binding of transcription and repair factors to DNA. These large multi-subunit complexes are broadly required for cellular differentiation and are mutated in >20% of human cancers. But how BAF complexes instruct cell fate through targeted complex assembly, transcription factor engagement, and regulation of gene expression is not fully understood. Our goal is to use biochemical and epigenomic assays to understand the BAF complex regulation of immune cell activation in disease. We also have a strong interest in understanding how cancer-associated mutations in BAF complex subunits impact therapeutic responses, particularly to immunotherapy. Our work has converged on the potential use of BAF complex inhibitors for cancer therapy and therapeutic control of inflammation.